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Abstract
Introduction: We examined if a combination of proliferation markers and estrogen receptor (ER) activity could
predict early versus late relapses in ER-positive breast cancer and inform the choice and length of adjuvant
endocrine therapy.
Methods: Baseline affymetrix gene-expression profiles from ER-positive patients who received no systemic therapy
(n = 559), adjuvant tamoxifen for 5 years (cohort-1: n = 683, cohort-2: n = 282) and from 58 patients treated with
neoadjuvant letrozole for 3 months (gene-expression available at baseline, 14 and 90 days) were analyzed. A
proliferation score based on the expression of mitotic kinases (MKS) and an ER-related score (ERS) adopted from
Oncotype DX® were calculated. The same analysis was performed using the Genomic Grade Index as proliferation
marker and the luminal gene score from the PAM50 classifier as measure of estrogen-related genes. Median values
were used to define low and high marker groups and four combinations were created. Relapses were grouped into
time cohorts of 0–2.5, 0–5, 5-10 years.
Results: In the overall 10 years period, the proportional hazards assumption was violated for several biomarker
groups indicating time-dependent effects. In tamoxifen-treated patients Low-MKS/Low-ERS cancers had
continuously increasing risk of relapse that was higher after 5 years than Low-MKS/High-ERS cancers [0 to 10 year,
HR 3.36; p = 0.013]. High-MKS/High-ERS cancers had low risk of early relapse [0–2.5 years HR 0.13; p = 0.0006], but
high risk of late relapse which was higher than in the High-MKS/Low-ERS group [after 5 years HR 3.86; p = 0.007].
The High-MKS/Low-ERS subset had most of the early relapses [0 to 2.5 years, HR 6.53; p < 0.0001] especially in node
negative tumors and showed minimal response to neoadjuvant letrozole. These findings were qualitatively
confirmed in a smaller independent cohort of tamoxifen-treated patients. Using different biomarkers provided
similar results.
Conclusions: Early relapses are highest in highly proliferative/low-ERS cancers, in particular in node negative
tumors. Relapses occurring after 5 years of adjuvant tamoxifen are highest among the highly-proliferative/high-ERS
tumors although their risk of recurrence is modest in the first 5 years on tamoxifen. These tumors could be the best
candidates for extended endocrine therapy.
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A sizable risk of late recurrence exists in estrogen receptor
(ER)-positive breast cancers after completion of 5 years of
adjuvant tamoxifen therapy [1,2]. This justifies consid-
eration of extended endocrine treatment in ER-positive
early-stage cancers. Letrozole after 5 years of tamoxifen was
f o u n dt or e d u c er e c u r r e n c ea n di m p r o v eo v e r a l ls u r v i v a l
[1], demonstrating that some micrometastatic foci retain
sensitivity to endocrine therapy even after 5 years of tam-
oxifen. Continuing tamoxifen to 10 years has also demon-
strated an overall survival benefit compared to 5 years of
t a m o x i f e n[ 2 ] .H o w e v e r ,t h es m all absolute benefit should
be weighted against the potential side effects of prolonged
endocrine therapy [3]. Available molecular markers do not
identify patients who are at high risk for late recurrence
(after 5 yrs) who would be the best candidates for extended
endocrine therapy. While the assays of Recurrence Score
and PAM50 predict prognosis for over 10 years, they are
most prognostic in the first 5 years and have limited
predictive values for late relapses [4,5]. Both tests rely
on measuring genes associated with proliferation and
estrogen receptor signaling [4,5]. However, the com-
bination of these markers in these tests is fixed and
does not allow detection of time-varying effect or in-
teractions between markers. Given the independent
prognostic and predictive values of proliferation and
estrogen signaling, we examined in a time-dependent
way whether a combination of proliferation, measured
by the Mitotic Kinase Gene Expression Score (MKS), and
ER-related gene expression, measured by an estrogen-
related gene expression score (ERS), could improve the
ability of these variables to predict early versus late re-
lapses in women with ER-positive breast cancer. This
information could help in selecting patients for extended
adjuvant endocrine therapy based on their persistent risk
for late relapses.
Methods
Tumor samples
Publicly available Affymetrix gene expression data from 683
patients (cohort 1; GSE6532 [6] GSE9195 [7] GSE17705 [8]
and GSE12093 [9]) with ER-positive breast cancers treated
with 5 years adjuvant tamoxifen and 559 ER-positive,
untreated, node-negative breast cancers (GSE2034 [10]
GSE7390 [11] GSE11121 [12] GSE5327 [13] GSE2990
[14] and GSE6532 [6]) were analyzed. Duplicated patients
were removed from the different datasets. We also assessed
an independent series of ER-positive patients treated
with adjuvant tamoxifen for 5 years (cohort 2, n = 282,
GSE26971 [15]) and 58 ER-positive patients treated with
neoadjuvant letrozole for 3 months for which gene expres-
sion profiles are available at baseline, 14 and 90 days after
beginning of the neoadjuvant treatment (GSE20181 [16]).
In this series, patients with a volume reduction higher than
50% over the 3-month treatmentp e r i o dw e r ec o n s i d e r e da s
clinical responders.
Although of limited sample size, cohort 2 was added
to our analysis to provide a qualitative confirmation of our
findings. Multivariate analysis of this series was not feas-
ible due to the small number of late events (n = 18). Gene
expression data used in this study were publicly available
and ethical approvals have been obtained as reported in
the original publications to which the datasets referred.
Description of molecular marker used for analysis
The proliferation score was calculated as the average ex-
pression of 12 mitotic kinases to produce the MKS as pre-
viously described [17]. The ERS was defined as the average
expression of the four genes from the ER-associated group
of the Oncotype DX test (Additional file 1: Table S1) [18].
None of these gene scores was developed or optimized on
the current data and therefore our results represent an
independent validation of their predictive and prognostic
values. To avoid over-fitting of an arbitrary marker thresh-
old to the data, median values were calculated over the
combined series of untreated patients and cohort 1 of the
tamoxifen-treated patients, and used to define high (that
is, above the median) and low (that is, below the median)
expression groups. A similar approach was used in cohort
2. By combining these two metrics, four biomarker groups
were created (low-MKS/high-ERS; low-MKS/low-ERS;
high-MKS/high-ERS and high-MKS/low-ERS).
In order to assess the robustness of our findings, we also
tested other measures of proliferation and ER signaling
(Additional file 1: Table S1) [19]. We assessed the ability
of four previously reported gene signatures to predict early
versus late relapse including the PAM50 subtypes [19], the
GGI (Genomic Grade Index) [14], the MammaPrint [20]
and the three-gene classifier (ER, human epidermal
growth factor receptor 2 (HER2) and Aurora Kinase A
(AURKA) [21] (Additional file 2: Supplementary Methods).
Statistical analysis
Statistical analyses were performed using BRB-ArrayTools
v4.1.0 - Beta_3 Release [22] and R software v2.9.0. All
statistical tests were two-sided. Distant event-free survival
was the primary endpoint. For each biomarker, the
proportional hazards assumption for Cox regression
model was assessed based on the scaled Schoenfeld
residuals.
In order to assess the time-dependent prognostic
value of our biomarkers groups, we examined recur-
rences rates in three distinct time intervals, including
0.0 to 2.5 years, 0.0 to 5.0 years and 5.0 to 10.0 years.
These intervals were selected because they correspond
to clinically important decision points. Patients at high
risk for relapse after 5 years of tamoxifen (that is, late
relapse) may be the optimal candidates for extended
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years before the conventional switch to aromatase inhibi-
tors is when the selection of the upfront endocrine treat-
ment (tamoxifen versus aromatase inhibitors) is made.
Landmark analysis of the Kaplan-Meier estimates by
biomarker groups in different time intervals was used. The
estimates of the hazard function by biomarker groups were
performed using the ‘muhaz’ R package (v 1.2.5) [23]. The
univariate and multivariate hazard ratios were estimated
using Cox regression analysis by the Wald test.
Results
Patient characteristics and correlation between clinical
and molecular variables
DEFS information was available for 673 of the 683 pa-
tients who received adjuvant tamoxifen in cohort 1. The
median follow up was 9.15 years. DEFS information was
available for 553 of the 559 patients who did not receive
systemic adjuvant therapy and their median follow up
was 9.9 years. The treated (cohort 1) and untreated pa-
tient cohorts were significantly different in age, tumor
(T) size, nodal status and histological grade (Table 1).
There was no association between the four molecular
groups (low-MKS/high-ERS, low-MKS/low-ERS, high-
MKS/high-ERS and high-MKS/low-ERS), nodal status or
age. However, high-MKS cancers had higher grade and
larger T size (T2/T3). The majority of HER2-positive tu-
mors (77.5%) were in the high-MKS/low-ERS group.
Time-varying prognostic values of clinical and molecular
variables in adjuvant tamoxifen-treated patients
We assessed the prognostic values of clinical and mo-
lecular variables for 10 years DEFS using Cox analysis in
tamoxifen-treated patients (cohort 1) and tested the as-
sumption of proportional hazards for each model (Table 2).
Age, T size and nodal status did not violate the propor-
tional hazards assumption but some molecular variables
showed violation of the proportional hazard assumption
indicating that their prognostic values varied over time.
We divided the time axis into less than 5 and 5 to 10
years and estimated the hazard ratios (HRs) separately
for each variable in both time periods. High-proliferation
tumors had a higher risk of relapse during the entire
period, but the risk decreased significantly over time.
HER2-positive tumors had a higher risk of relapse only
during the first 5 years. The ERS also had a strong time
dependent effect (P = 0.0008 over 10 years). The HRs for
recurrence of low- versus high-ERS groups in the first
2.5 years, from 2.5 to 5.0 years, and >5.0 years were 8.36
(95% CI 3.37, 21.7), 1.93 (95% CI 1.07, 3.48) and 0.91
(95% CI 0.50, 1.66), respectively. The four-group model
obtained by combining MKS and ERS had the strongest
time-dependent effect (P <0.0001). Kaplan-Meier analysis
of the four biomarker groups is represented in Figure 1
for the tamoxifen-treated patients (Figure 1A). The time-
dependent effect of biomarkers was qualitatively similar
in node-negative (Figure 1B) and -positive (Figure 1C)
tumors.
Time-varying prognostic values of clinical and molecular
variables in untreated patients
We performed a similar analysis in patients who received
no adjuvant therapy (Additional file 3: Table S2). Age and
Tsize did not violate the proportional hazards assumption
over 10 years. The low-ERS group had a constant, slightly
higher risk of recurrence than the high-ERS group in
the first 5 years (HR 1.90, 95% CI 1.29, 2.80; P = 0.001)
without a significant violation of the proportional
hazard assumption (P = 0.127). High-proliferation
tumors (that is, high histological grade, high-MKS,
high-GGI, luminal B) had a higher risk of relapse over
the entire 10-year period, but the risk decreased signifi-
cantly after the first 5 years. There was a trend for a higher
relative rate of relapse in low proliferation tumors after 5
years (Additional file 4: Figure S1). In the absence of endo-
crine therapy, the four-group model had only a trend
for time-dependent effect (P =0 . 0 6 5 )( F i g u r e1 D ) .
Prediction of early and late relapse in tamoxifen-treated
patients
Among the tamoxifen-treated patients, cancers with
low proliferation and low ERS were associated with a
continuously increasing risk of relapse over 10 years
(Table 2), that was higher between 5 to 10 years than
in 0 to 5 years (HR 3.36, 95% CI 1.29, 8.73; P = 0.013)
(Additional file 4: Figure S2A). Low proliferation and
high-ERS tumors had an excellent prognosis at 10 years,
even after stopping tamoxifen at 5 years (Figure 1). In
the high-proliferation group, ERS had an even stronger
time-dependent prognostic value (P <0.0001). Among high
proliferation cancers, the HRs for the low- versus high-ERS
groups in the time periods 0.0 to 2.5, 2.5 to 5.0, and >5.0 to
10.0 years were 11.8, 95% CI 2.83, 49.3; P = 0.0007, 1.80,
95% CI 0.88, 3.69; P = 0.110, and 0.23, 95% CI 0.08,
0.61; P = 0.003), respectively indicating very high risk
of early relapse among high-proliferation low-ESR can-
cers (Additional file 4: Figure S2A). This was similar in
node-negative (Figure 2A) and -positive (Figure 2B)
patients. To test if this effect was independent of the
threshold used, we also examined the time dependence
when ESR was assessed by tertiles or as continuous var-
iables. The lowest tertile of ERS compared to the highest
showed a higher risk of early relapse within 0 to 5 years
(HR 3.93, 95% CI 1.99, 7.75; P <0.0001) and a lower risk of
late relapse between 5 to 10 years (HR 0.09, 95% CI 0.01,
0.70; P = 0.021) (Additional file 4: Figure S3). ERS analyzed
as a continuous variable produced similar results, indicating
a robust finding.
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of ER-associated genes for late recurrence is different in
low- and high-proliferation cancer groups (Additional file 4:
Figure S2A). In the 5- to 10-year interval, Cox analysis in-
cluding MKS and ERS as continuous variables and their
interaction term showed that they were each independently
significant (P = 0.035 and P = 0.048, respectively). The
interaction term was also significant (P = 0.027). In the
0.0- to 2.5-year interval, almost all recurrences occurred in
the high-MKS/low-ERS group (HR 6.53, 95% CI 3.48, 12.2;
P <0.0001) compared to other groups (Additional file 4:
Figure S4B). In this high-risk group the nodal status was
not significantly prognostic (P = 0.098) (Additional file 4:
Figure S4F), but in the other molecular groups enriched for
more endocrine-sensitive tumors, almost all relapses were
observed in the node-positive cohort (HR 6.56, 95% CI
1.83, 23.5; P = 0.0008) (Additional file 4: Figure S4E).
The average ERS of high-MKS tumors that relapsed
at 0.0 to 2.5, 2.5 to 5.0 and >5.0 to 10.0 years was
progressively and significantly higher in late relapses
(Additional file 4: Figure S5B).
Results of a Cox multivariate analysis for the 0.0- to
2.5- and 5.0- to 10.0-year time periods are presented in
Table 3. After adjustment for clinical variables, high-MKS/
high-ERS (HR 4.59, 95% CI 1.56, 13.5; P = 0.006) and
low-MKS/low-ERS groups (HR 3.53, 95% CI 1.21, 10.2;
Table 1 Summary of patient and tumor characteristics
Tamoxifen
cohort 1
Untreated Low MKS High MKS Tamoxifen
cohort 2 High ERS Low ERS High ERS Low ERS
Characteristic N % N % P
a N%N%N%N% P
b N%
Patients 683 559 373 248 248 373 282
Age, years
≤50 43 6.3 240 42.9 <0.0001 82 22.0 47 19.0 57 23.0 96 25.7 0.247 8 2.8
>50 498 72.9 306 54.8 240 64.3 172 69.3 160 64.5 233 62.5 176 62.4
Unknown 142 20.8 13 2.3 51 13.7 29 11.7 31 12.5 44 11.8 98 34.8
Tumor (T) stage
T1 214 31.3 199 35.6 <0.0001 145 38.9 102 41.1 74 29.8 92 24.7 0.003 109 38.7
T2/T3 293 42.9 140 25.0 126 33.8 82 33.1 84 33.9 141 37.8 168 59.5
Unknown 176 25.8 220 39.4 102 27.3 64 25.8 90 36.3 140 37.5 5 1.8
Nodal status
Negative 403 59.0 559 100.0 <0.0001 295 79.1 192 77.4 191 77.0 284 76.1 0.962 147 52.1
Positive 258 37.8 0 0.0 76 20.4 50 20.2 52 21.0 80 21.5 111 39.4
Unknown 22 3.2 0 0.0 2 0.5 6 2.4 5 2.0 9 2.4 24 8.5
Grade
1 108 15.8 66 11.8 0.0002 86 23.1 54 21.8 18 7.3 16 4.3 <0.0001 26 9.2
2 258 37.8 242 43.3 159 42.6 105 42.3 108 43.5 128 34.3 114 40.4
3 111 16.3 152 27.2 29 7.8 32 12.9 63 25.4 139 37.3 44 15.6
Unknown 206 30.2 99 17.7 99 26.5 57 23.0 59 23.8 90 24.1 98 34.8
HER2 by gene
c
HER2-positive 27 4.0 44 7.9 0.169 1 0.3 8 3.2 7 2.8 55 14.8 <0.0001 - 0.0
HER2-negative 647 94.7 515 92.1 371 99.4 239 96.4 239 96.4 313 83.9 - 0.0
Unknown 9 1.3 0 0.0 1 0.3 1 0.4 2 0.8 5 1.3 282 100.0
Distant events, time cohorts
0 to 10 yrs 137 144 - 42 37 65 137 - 64
0 to 2.5 yrs 46 55 8 9 17 67 26
2.5 to 5 yrs 48 55 19 10 21 53 20
>5 yrs 43 34 15 19 26 17 18
Unknown 10 6 2 6 3 5 -
aOnly patients with known clinical information were considered for comparison between tamoxifen-treated (cohort 1) and untreated patients.
bOnly patients with
known clinical information were considered for comparison among the four molecular groups. P-values in boldface were statistically significant at P <0.05. These
molecular groups referred to the tamoxifen-treated (cohort 1) and untreated patients.
cHER2 status was defined according to Haibe-Kains et al.[ 21]. N, number of
patients; MKS, mitotic kinase score; ERS, estrogen-related score; HER2: human epidermal growth factor receptor 2.
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the low-MKS/high-ERS group.
Prediction of early and late relapse in untreated patients
ERS was not predictive of early versus late relapse when
proliferation (MKS) was low (Additional file 3: Table S2).
In the high-MKS group, there was a constantly higher risk
of relapse for the low-ERS group over 10 years (HR 1.80,
95% CI 1.18, 2.73); P = 0.006) (Figure 2C and Additional
file 3: Table S2). In the first 2.5 years, the high-MKS/
low-ERS group had a higher risk of relapse than the
other groups combined (Additional file 4: Figure S4A)
and the HER2-positive patients were also at significantly
higher risk of relapse. Cox multivariate analysis showed
that none of the variables was prognostic for late relapse
(Table 3). When the average ERS was compared between
tumors relapsing at 0.0- to 2.5-, 2.5- to 5.0- and 5.0- to
10-year time intervals we did not observe any significant
difference by proliferation group (Additional file 4:
Figure S5C and S5D).
A combination of proliferation and ER-related genes can
further risk-stratify patients for early and late relapse
within conventional prognostic risk categories assigned
by PAM50 and Mammaprint
To test the robustness of our observations, we performed
the same analysis substituting the genomic grade index for
MKS as a proliferation marker and the luminal gene score
from the PAM50 classifier for the ERS as a measure of
estrogen-related genes. Results using the combination of
these markers also showed higher risk of early relapse in
highly proliferative, low estrogen-score cancers and sub-
stantial risk for late relapse in highly proliferative and high
estrogen-score tumors (Additional file 4: Figure S6).
We also noted that ESR1 mRNA expression levels did
not correlate strongly with either the ERS or luminal
Table 2 Univariate Cox analysis of clinical variables and molecular markers for tamoxifen-treated patients (cohort-1)
Variable 0 to 10 years DEFS 0 to 5 years DEFS 5 to 10 years DEFS
Hazard ratio
(95% CI)
P
a P
b Hazard ratio
(95% CI)
P
a P
b Hazard ratio
(95% CI)
P
a P
b
Age 1.02 (1.00, 1.04) 0.021 0.657 1.02 (0.99, 1.04) 0.153 0.214 1.04 (1.00, 1.08) 0.042 0.168
Stage T2/3 vs T1 2.71 (1.76, 4.19) <0.0001 0.581 2.51 (1.47, 4.26) 0.0007 0.211 3.14 (1.49, 6.64) 0.003 0.164
Node-positive vs -negative 2.47 (1.75, 3.48) <0.0001 0.964 2.51 (1.65, 3.82) <0.0001 0.732 2.67 (1.44, 4.97) 0.002 0.941
Grade
Intermediate vs low 2.19 (1.20, 3.99) 0.011 0.11 3.97 (1.57, 9.99) 0.003 0.175 1.04 (0.44, 2.45) 0.934 0.192
High vs low 2.96 (1.56, 5.62) 0.0009 5.05 (1.92, 13.3) 0.001 1.66 (0.67, 4.12) 0.277
HER2-positive vs -negative 2.64 (1.43, 4.90) 0.002 0.029 3.68 (1.91, 7.10) 0.0001 0.369 0.72 (0.11, 5.26) 0.75 0.141
High MKS vs low MKS 2.96 (2.07, 4.25) <0.0001 0.04 3.89 (2.42, 6.24) <0.0001 0.473 1.90 (1.04, 3.46) 0.036 0.377
Low ERS vs high ERS 2.00 (1.41, 2.83) <0.0001 0.0008 3.26 (2.04, 5.19) <0.0001 0.091 0.91 (0.50, 1.66) 0.763 0.728
MKS/ERS combined groups
LowMKS/lowERS vs lowMKS/highERS 2.37 (1.29, 4.35) 0.005 <0.0001 1.98 (0.87, 4.51) 0.104 0.285 3.36 (1.29, 8.73) 0.013 0.862
HighMKS/highERS vs lowMKS/highERS 3.66 (2.04, 6.57) <0.0001 2.46 (1.09, 5.54) 0.029 6.59 (2.62, 16.6) <0.0001
HighMKS/lowERS vs lowMKS/highERS 5.35 (3.12, 9.17) <0.0001 7.78 (3.97, 15.3) <0.0001 1.46 (0.45, 4.79) 0.531
Other genomic signatures
High GGI vs low GGI 2.73 (1.94, 3.86) <0.0001 0.005 3.81 (2.43, 5.97) <0.0001 0.296 1.64 (0.90, 2.99) 0.109 0.02
Mammaprint poor vs good 2.93 (1.91, 4.49) <0.0001 0.22 3.59 (2.02, 6.30) <0.0001 0.768 2.30 (1.16, 4.56) 0.017 0.184
Three-gene model SCMGENE
ER+/HER2-highP vs ER+/HER2-lowP 2.13 (1.47, 3.08) <0.0001 0.017 2.58 (1.59, 4.18) 0.0001 0.585 1.60 (0.87, 2.95) 0.127 0.197
HER2+ vs ER+/HER2-lowP 4.06 (2.09, 7.86) <0.0001 6.63 (3.17, 13.9) <0.0001 0.89 (0.12, 6.64) 0.909
ER-/HER2- vs ER+/HER2-lowP 2.55 (1.01, 6.42) 0.048 4.70 (1.79, 12.3) 0.002 NA
PAM50
LumB vs lumA 3.01 (2.01, 4.51) <0.0001 0.004 3.84 (2.21, 6.65) <0.0001 0.109 2.26 (1.20, 4.24) 0.011 0.147
HER2 vs lumA 8.88 (4.36, 18.1) <0.0001 14.4 (6.37, 32.8) <0.0001 2.37 (0.31, 17.9) 0.403
Basal vs lumA 3.03 (1.07, 8.58) 0.036 6.48 (2.17, 19.4) 0.0008 NA
aP-value generated by univariate Cox analysis.
bP-value for the test of the proportional hazard assumption based on the scaled Schoenfeld residuals. P-values in
boldface were statistically significant at P<0.05. DEFS, distant event-free survival; MKS, mitotic kinase score; ERS, estrogen-related score; GGI, genomic grade index;
Lum, luminal; ER+/HER2-lowP, ER-positive/human epidermal growth factor receptor 2 (HER2)-negative low proliferation; ER+/HER2-highP, ER-positive/HER2-
negative high proliferation; NA, not applicable.
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molecular information not provided by ESR1 expression
levels alone (Additional file 4: Figure S7).
Furthermore, the four biomarker groups based on MKS
and ERS could further risk-stratify patients for early
(<5 years) and late relapses (within 5 to 10 years) within
prognostic risk groups assigned by three first-generation
genomic prognostic predictors, including the three-gene
model (Figure 3A and 3B), luminal A and B molecular
subtypes by PAM50 (Figure 3C and 3D) and low- and
high-risk groups by Mammaprint (Figure 3E and 3F).
Confirmation of results in an independent cohort of
patients treated with adjuvant tamoxifen
The patient characteristics of an independent series of
ER-positive patients treated with adjuvant tamoxifen are
described in Table 1. The median follow up was 7.2 years.
The median cutoff point was applied to MKS and ERS.
The time-varying pattern of distant relapse was qualitatively
similar to that observed in the previously described cohort
(Figure 4A-C). In the high-proliferation group the risk of
r e l a p s ef o rt h eh i g h - E R Sg r o u pw a sl o w e ri nt h ef i r s t5
years (P = 0.057) and higher after 5 years (P = 0.072)
(Figure 4D). We also confirmed that in the first 2.5 years
the majority of the relapses occurred in the high-MKS/
low-ERS groups in node-negative but not in node-positive
patients (Additional file 4: Figure S8).
Predictive values of proliferation and ER-associated genes
in tumors treated with neoadjuvant letrozole
We evaluated the relationship between MKS and ERS
and clinical and molecular response to neoadjuvant
letrozole (n = 58). Molecular response was defined as
d o w n r e g u l a t i o no ft h eM K S ,a sam e a s u r eo fp r o l i f e r a -
tion, at 14 and 90 days during neoadjuvant therapy.
Among cancers with high proliferation (that is, high
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Figure 1 Kaplan-Meier estimates of distant event-free survival (DEFS) by marker groups in tamoxifen-treated and untreated patients.
Kaplan-Meier estimates of 10-year DEFS of the four biomarker groups obtained by combining low and high MKS (mitosis kinome score) and ERS
(estrogen-related score). Results are plotted separately for tamoxifen-treated (all patients) (A), tamoxifen-treated (node negative) (B),t a m o x i f e n - t r e a t e d
(node positive) (C), and tamoxifen-untreated patients (D). loP, low MKS; hiP, high MKS; loER, low ERS; hiER, high ERS.
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Figure 2 Time-dependent assessment of estrogen-related score (ERS) in the high mitosis kinase score (MKS)-group in both
tamoxifen-treated and untreated patients. Landmark analyses of the Kaplan-Meier estimates of distant event-free survival (DEFS) for highly
proliferative tumors (high-MKS) according to ERS groups (high and low) during the first 2.5 years (left side of each panel), from 2.5 to 5 years
(center of each panel) and from 5 to 10 years (right side of each panel) are shown. Results are plotted separately for tamoxifen-treated, node-negative
(A), tamoxifen-treated, node-positive (B) and tamoxifen-untreated, node-negative (C) patients.
Table 3 Multivariate Cox analysis of clinical variables and marker groups in tamoxifen-treated (cohort 1) and
untreated patients
Tamoxifen-treated patients (cohort 1) Untreated patients
0.0 to 2.5 years
a 5.0 to 10.0 years
a,c 0.0 to 2.5 years
b 5.0 to 10.0 years
b,c
Variable Hazard ratio
(95% CI)
P Hazard ratio
(95% CI)
P Hazard ratio
(95% CI)
P Hazard ratio
(95% CI)
P
Age, analyzed as a continuous variable 1.04 (0.99, 1.08) 0.071 1.02 (0.98, 1.07) 0.279 1.01 (0.98, 1.05) 0.357 1.04 (0.99, 1.08) 0.063
Tumor (T) stage, T2/3 vs T1 2.29 (0.87, 6.08) 0.094 2.90 (1.22, 6.91) 0.016 1.88 (0.74, 4.80) 0.183 1.22 (0.48, 3.12) 0.677
Nodal status, positive vs negative 2.92 (1.23, 6.88) 0.014 2.46 (1.15, 5.23) 0.021 --
Grade 2 or 3 vs 1 1.51 (0.33, 6.78) 0.592 0.72 (0.31, 1.69) 0.451 2.13 (0.28, 16.4) 0.467 1.07 (0.29, 3.95) 0.923
HER2-positive vs -negative 1.42 (0.33, 6.78) 0.528 1.63 (0.31, 1.69) 0.667 4.24 (1.36, 13.1) 0.013 2.89 (0.57, 14.6) 0.198
MKS/ERS (ref lowMKS/highERS)
lowMKS/lowERS 2.65 (0.48, 14.7) 0.269 3.53 (1.21, 10.2) 0.021 1.67 (0.10, 27.1) 0.717 0.46 (0.09, 2.33) 0.349
highMKS/highERS 1.28 (0.18, 9.23) 0.807 4.59 (1.56, 13.5) 0.006 11.6 (1.41, 95.2) 0.023 1.82 (0.53, 6.27) 0.343
highMKS/lowERS 10.0 (2.21, 45.5) 0.003 0.95 (0.20, 4.70) 0.947 9.56 (1.17, 77.8) 0.035 1.51 (0.44, 5.14) 0.508
Note: only patients with all data available were considered in multivariate analysis.
aTime interval 0.0 to 2.5 years: 434 patients (29 events); time interval 5.0 to 10.0
years: 323 patients (34 events).
bTime interval 0.0 to 2.5 years: 320 patients (20 events); time interval 5.0 to 10.0 years: 256 patients (19 events). Cox multivariate
analysis was performed also excluding tumor stage (which accounted for the majority of the missing data) with similar results (458 patients (40 events) and 349
patients (28 events) in 0.0 to 2.5 and 5.0 to 10 years, respectively).
cP = 0.0002 (tamoxifen, 0.0 to 2.5 years), P = 0.003 (tamoxifen, 5.0 to 10.0 years), P = 0.006
(untreated, 0.0 to 2.5 years), P = 0.361 (untreated, 5.0 to 10.0 years) for the comparison of the multivariate models with and without the MKS/ERS groups
(by the likelihood-ratio test). MKS, mitotic kinase score; ERS, estrogen-related score. P-values in boldface were statistically significant at P <0.05.
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Figure 3 Time-dependent assessment of combinations of different markers of proliferation and estrogen receptor (ER)-related genes.
Landmark analyses of the Kaplan-Meier estimates of distant event-free survival (DEFS) during the first 5 years (left side of each panel) and from 5
to 10 years (right side of each panel) are shown for tamoxifen-treated patients according to four biomarker groups by combining mitosis kinase
score (MKS) (low and high) and estrogen-related score (ERS) (high and low) in ER-positive/human epidermal growth factor (HER)2-negative low
proliferation tumors (A) and high-proliferation tumors (B) by the three-gene model [21]; in Luminal A (C) and luminal B (D) by PAM50; and in
low risk (E) and high risk (F) by Mammaprint. loP, low MKS; hiP, high MKS; loER, low ERS; hiER, high ERS.
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http://breast-cancer-research.com/content/15/5/R86MKS) at baseline (n = 26), the clinical response rates
were 47% (7/15) and 100% (11/11) for the low-ERS and
high-ERS groups, respectively (P = 0.013). High-ERS
cancers also had a more significant downregulation of
proliferation at 14 (P = 0.028) and at 90 days (P =0 . 0 4 5 )
compared to low-ERS tumors in response to letrozole
therapy (Figure 5). These findings confirm lesser endo-
crine sensitivity of low-ERS cancers and are consistent
with the observation of high early relapse rates among
the high MKS/low ERS cancers.
Discussion
The potential time-dependency of prognostic and pre-
dictive variables is well-known [11,24,25], but it is
rarely studied purposefully. In this paper we examined
the time-dependent interaction of proliferation [17] and
ER-related gene expression [18,26] with the risk of early
versus late recurrence in ER-positive early-stage breast
cancer. We show that the high risk of relapse of highly
proliferative tumors decreases over time in both un-
treated and tamoxifen-treated patients [11,24]. We also
discovered a strong time-dependent prognostic inter-
action between the ERS and proliferation in tamoxifen-
treated patients. The low risk of early recurrence in high-
ERS, high-proliferation cancers during the first 5 years of
active therapy converts into a higher risk of recurrence
after 5 years. Highly proliferative cancers with strong
ER signaling (high-MKS/high-ERS) show the greatest
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Figure 4 Prognostic values of the four biomarker groups in the second cohort of tamoxifen-treated patients. Kaplan-Meier estimates of 10-year
distant event-free survival (DEFS) of the four biomarker groups obtained by combining low and high mitosis kinase score (MKS) and estrogen-related score
(ERS) in all patients (A) and node-negative patients (B). Annual hazard rates for distant recurrences by biomarker-group estimates using kernel-based
m e t h o d sf o ra l lp a t i e n t s(C). Landmark analyses of the Kaplan-Meier estimates of DEFS during the first 5 years (left side of the panel) and from 5 to 10 years
(right side of the panel) is shown for the high-MKS groups by ERS (high and low) (D). loP, low MKS; hiP, high MKS; loER, low ERS; hiER, high ERS).
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http://breast-cancer-research.com/content/15/5/R86absolute increase for risk of late relapse after comple-
tion of 5 years of endocrine therapy, and therefore may
be the best candidates for extended endocrine treat-
ment. Among the low-proliferation cancers, the low-
ERS group had constantly higher risk of relapse over
the 10-year period compared to low-proliferation, high-
ERS cancers. Extended endocrine therapy in this group also
deserves further study. The time-dependent interaction
between proliferation and estrogen signaling in
predicting recurrence may explain why biomarkers
that do not take into account such information (PAM50,
Oncotype DX) do not predict late recurrences well [4,5].
The majority of the relapses within the first 2.5 years
on tamoxifen occurred in the high-proliferation/low-ERS
group. In a series of ER-positive patients treated with
neoadjuvant letrozole, this group also had low clinical re-
sponse rates and had minimal decrease in proliferation
metrics [27]. These data suggest that the high-proliferation/
low-ERS group is enriched in tumors intrinsically resistant
to both tamoxifen and letrozole and in part explain why the
use of upfront aromatase inhibitors (AIs) was not superior
to the sequence of tamoxifen followed by an aromatase in-
hibitor in unselected patients [28,29]. Clinical trials could
be designed and investigate specific strategies to overcome
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Figure 5 Predictive value of the estrogen-related score (ERS) in the high-proliferation group after neoadjuvant letrozole. The dynamic
change of proliferation measured by mitosis kinase score (MKS) at baseline, 14 and 90 days in patients with baseline high proliferation treated
with neoadjuvant letrozole in the high-ERS (A) and low-ERS (B) groups (red line = clinical response; blue line = non responder; green line = clinical
information not available). (C) Box plot describing the proliferation at 14 and 90 days in the high-ERS and low-ERS groups. A comparison between
MKS values in different groups was performed by Wilcoxon rank-sum test.
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http://breast-cancer-research.com/content/15/5/R86intrinsic resistance in these molecular groups. Additionally,
node-negative and node-positive tumors show a different
pattern of relapse in this early period, indeed almost all
the recurrences in the molecular groups different from
the high-proliferation/low-ERS group occur in node-
positive cancers (P = 0.0008). The observation is con-
sistent with findings in the BIG1-98 trial that showed a
benefit from upfront letrozole compared to tamoxifen
only in node-positive tumors during the short median
follow up of 2.5 years [30].
Highly proliferative tumors relapsing after adjuvant tam-
oxifen had a progressively higher ERS score in late recur-
rences compared to early recurrences, but the same
association was not observed in untreated tumors. One can
speculate that early relapses are most common in tumors
intrinsically resistant to endocrine treatment, while late re-
currences occur also in tumors that could have relapsed
earlier without treatment, but relapse was delayed due to
adjuvant therapy. Our observation could also explain why
in different reports the risk-reduction is modest around
20% for upfront AIs compared to tamoxifen [31], while it
increases to 30% when tamoxifen is switched to an AI after
2 to 3 years [31], and the risk reduction is up to 50% when
the AI is administered after 5 years of tamoxifen [1].
Our results are consistent with other reports and show
that tumor size and nodal status remain independent prog-
nostic factors. Clinical and molecular information, particu-
larly nodal status should be used in combination for
decision-making about extended endocrine treatments [32].
We acknowledge that the different characteristics of
patients in the tamoxifen-treated and untreated cohorts call
for caution in any comparison between the two groups.
Also, our analysis is not based on data from randomized
clinical trials but from prospectively assembled cohorts
of cases for prognostic marker studies. The cohorts have
been annotated and published in peer-reviewed journals
[21], and the validity of clinical information has been
demonstrated in several different studies [6,8,33]. The
generalizability of our results was assessed in an independ-
ent cohort of tamoxifen-treated patients, and also sup-
ported by recently presented data by other groups [34,35].
Conclusions
Our findings suggest that patients with highly prolifera-
tive (high MKS or high GGI) and high-ER breast cancers
(high expression of ER-related genes both adopted from
Oncotype DX or from PAM50) have the highest absolute
risk for late relapse tumors, despite the fact that their risk
of recurrence is modest in the first 5 years on tamoxifen.
These tumors could be the best candidates for extended
endocrine therapy. Patients with low proliferation and low-
ER-related genes also remain at risk for late relapses, and
benefit from extended endocrine treatment with aromatase
inhibitors should be also assessed.
Early relapses (in the first 2.5 years) are highest in highly
proliferative/low-ERS cancers, in particular in node-negative
tumors, and this group also had minimal response to
neoadjuvant letrozole. These findings suggest that this
molecular group is enriched in tumors intrinsically resist-
ant to endocrine therapy (both tamoxifen and letrozole)
and in part can explain why upfront AIs were not super-
ior to the sequence of tamoxifen followed by an AI in
unselected patients.
Overall, the combined use of markers of proliferation
and ER-related genes can inform the design of future
adjuvant trials and assist in the selection of patients for
extended endocrine treatment.
Additional files
Additional file 1: Table S1. Genes and probe sets used to define the
mitosis kinase score (MKS), estrogen-related score (ERS) and luminal
estrogen-related genes.
Additional file 2: Supplementary methods.
Additional file 3: Table S2. Univariate Cox analysis of clinical variables
and molecular markers for untreated patients.
Additional file 4: Figure S1. Time-dependent assessment of grade,
genomic grade index (GGI) and PAM50 in untreated patients.
Figure S2. Hazard rates for recurrences by biomarker groups in
untreated and tamoxifen-treated patients. Figure S3. Time-dependent
effect of estrogen-related score (ERS) by tertiles in high-mitosis kinase
score (MKS) tumors (tamoxifen-treated patients). Figure S4. Prognostic
values of biomarkers for early relapse in untreated and tamoxifen-treated
patients. Figure S5. Baseline expression of ERS for tumor relapse in
different time cohorts. Figure S6. Assessment of the time-dependent
prognostic values of MKS, GGI and estrogen receptor (ER)-related luminal
genes. Figure S7. Correlation between ESR1, ERS and luminal ER-related
genes. Figure S8. Prognostic values of biomarkers for early relapse in
tamoxifen-treated patients (cohort 2).
Abbreviations
AI: Aromatase inhibitors; DEFS: Distant event-free survival; ER: Estrogen
receptor; ERS: Estrogen-related score; GGI: Genomic grade index;
HER2: Human epidermal growth factor receptor 2; HR: Hazard ratio;
MKS: Mitosis kinase score; T: Tumor.
Competing interests
W Fraser Symmans: Consultant or Advisory Role: Nuvera Biosciences
(uncompensated); Stock Ownership: Nuvera Biosciences. C Sotiriou is named
inventor on a patent application for the Gene expression Grade Index (GGI) used
in this study. The other authors declare that they have no competing interests.
Authors’ contributions
GB conceived and designed the study, performed the statistical analysis,
contributed to the acquisition and collection of the gene expression data,
data interpretation and writing the manuscript. LP and LG contributed to the
study design, data analysis and interpretation and in writing the manuscript.
TK contributed to the acquisition and collection of the gene expression data,
statistical analysis, data interpretation and writing the manuscript. TI
contributed to statistical analysis, data interpretation and writing the
manuscript. YQ contributed to the statistical analysis and gene expression
data normalization. AR, VM, MS, UH, SB, CS, BHK and WFS contributed to the
acquisition and collection of the gene expression data, participated in data
assembling and interpretation, and critically revised the manuscript. CMK, LS,
AF, GDC and MZ participated in data assembling, analysis and interpretation
and in writing the manuscript. All authors read and approved the final
manuscript.
Bianchini et al. Breast Cancer Research 2013, 15:R86 Page 11 of 13
http://breast-cancer-research.com/content/15/5/R86Acknowledgements
Funding: the Fondazione Michelangelo for the advancement of the study
and treatment of cancer grant to (GB), the Associazione Italiana per la Ricerca
sul Cancro (AIRC) grant to (LG, IG 4915) and grant to (GB, MFAG 13428), the
Breast Cancer Research Foundation (New York, NY) grant to (LP and WFS), the
H.W.&J. Hector-Foundation (TK) and the Margarete Bonifer-Foundation (TK). The
funders did not have any involvement in the design of the study, the
collection, analysis and interpretation of the data, the writing of the article, or
the decision to submit the article for publication.
Author details
1San Raffaele - Scientific Institute, Milan, Italy.
2Yale Cancer Center, New
Haven, CT, USA.
3J.W. Goethe University, Frankfurt, Germany.
4University
Graduate School of Medicine and Dentistry, Okayama, Japan.
5University
Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
6Mater Misericordiae University Hospital, Dublin, Ireland.
7University Hospital
Hamburg-Eppendorf, Hamburg, Germany.
8Gutenberg-University, Mainz,
Germany.
9The University of Texas M. D. Anderson Cancer Center, Houston,
TX, USA.
10Translational Research Unit and Istituto Toscano Tumori, Prato,
Italy.
11Institut Jules Bordet, Univerité Libre de Bruxelies, Brussels, Belgium.
12Bioinformatics and Computational Genomics Laboratory, Institut de
recherches cliniques de Montréal, Montreal, Canada.
Received: 19 April 2013 Accepted: 16 August 2013
Published: 23 September 2013
References
1. Jin H, Tu D, Zhao N, Shepherd LE, Goss PE: Longer-term outcomes of
letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG
MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol 2012,
30:718–721.
2. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar
VHM, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A,
Forbes JF, Haddad P, Hou M-F, Inbar M, Khaled H, Kielanowska J, Kwan W-H,
Mathew BS, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski
T, Rajan B, et al: Long-term effects of continuing adjuvant tamoxifen to 10
years versus stopping at 5 years after diagnosis of oestrogen receptor-
positive breast cancer: ATLAS, a randomised trial. Lancet 2013, 381:805–816.
3. Amir E, Seruga B, Niraula S, Carlsson L, Ocana A: Toxicity of adjuvant endocrine
therapy in postmenopausal breast cancer patients: a systematic review and
meta-analysis. JN a t lC a n c e rI n s t2011, 103:1299–1309.
4. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P,
Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN,
Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne
CK, Hayes DF: Prognostic and predictive value of the 21-gene recurrence
score assay in postmenopausal women with node-positive, oestrogen-
receptor-positive breast cancer on chemotherapy: a retrospective analysis
of a randomised trial. Lancet Oncol 2010, 11:55–65.
5. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider
J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ: A
comparison of PAM50 intrinsic subtyping with immunohistochemistry and
clinical prognostic factors in tamoxifen-treated estrogen receptor-positive
breast cancer. Clin Cancer Res 2010, 16:5222–5232.
6. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A,
Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M,
Piccart MJ, Sotiriou C: Definition of clinically distinct molecular subtypes in
estrogen receptor-positive breast carcinomas through genomic grade.
JC l i nO n c o l2007, 25:1239–1246.
7. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C,
Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP,
Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C: Predicting
prognosis using molecular profiling in estrogen receptor-positive breast
cancer treated with tamoxifen. BMC Genomics 2008, 9:239.
8. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P,
Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T,
Valero V, Booser DJ, Hortobagyi GN, Pusztai L: Genomic index of sensitivity
to endocrine therapy for breast cancer. J Clin Oncol 2010, 28:4111–4119.
9. Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, Paradiso A, Harbeck N,
Span PN, Hicks DG, Crowe J, Tubbs RR, Budd GT, Lyons J, Sweep FC, Schmitt M,
Schittulli F, Golouh R, Talantov D, Wang Y, Foekens JA: The 76-gene signature
defines high-risk patients that benefit from adjuvant tamoxifen therapy.
Breast Cancer Res Treat 2009, 116:303–309.
10. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D,
Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D,
Foekens JA: Gene-expression profiles to predict distant metastasis of
lymph-node-negative primary breast cancer. Lancet 2005, 365:671–679.
11. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G,
Delorenzi M, Zhang Y, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL,
Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C: Strong time
dependence of the 76-gene prognostic signature for node-negative
breast cancer patients in the TRANSBIG multicenter independent
validation series. Clin Cancer Res 2007, 13:3207–3214.
12. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA,
Hengstler JG, Kolbl H, Gehrmann M: The humoral immune system has a
key prognostic impact in node-negative breast cancer. Cancer Res 2008,
68:5405–5413.
13. Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, Kreike B, Zhang
Y, Wang Y, Ishwaran H, Foekens JA, van de Vijver M, Massague J: Lung
metastasis genes couple breast tumor size and metastatic spread. Proc
Natl Acad Sci USA 2007, 104:6740–6745.
14. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P,
Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H,
Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M:
Gene expression profiling in breast cancer: understanding the
molecular basis of histologic grade to improve prognosis. J Natl Cancer
Inst 2006, 98:262–272.
15. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R,
Jelen A, Sevelda P, Freibauer C, Muller V, Janicke F, Schmidt M, Kolbl H,
Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE,
Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M: A new
molecular predictor of distant recurrence in ER-positive, HER2-negative
breast cancer adds independent information to conventional clinical risk
factors. Clin Cancer Res 2011, 17:6012–6020.
16. Miller WR, Larionov A, Anderson TJ, Evans DB, Dixon JM: Sequential changes
in gene expression profiles in breast cancers during treatment with the
aromatase inhibitor, letrozole. Pharmacogenomics J 2012, 12:10–21.
17. Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L,
V a l e r oV ,H o r t o b a g y iG N ,S y m m a n sW F ,G i a n n iL ,P u s z t a iL :Prognostic and
therapeutic implications of distinct kinase expression patterns in
different subtypes of breast cancer. Cancer Res 2010, 70:8852–8862.
18. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG,
Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N: A
multigene assay to predict recurrence of tamoxifen-treated, node-
negative breast cancer. N Engl J Med 2004, 351:2817–2826.
19. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S,
Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS,
Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS: Supervised
risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol
2009, 27:1160–1167.
20. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber
GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas
A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend
SH, Bernards R: A gene-expression signature as a predictor of survival in
breast cancer. N Engl J Med 2002, 347:1999–2009.
21. Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J,
Sotiriou C: A three-gene model to robustly identify breast cancer
molecular subtypes. J Natl Cancer Inst 2012, 104:311–325.
22. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y: Analysis of gene
expression data using BRB-ArrayTools. Cancer Inform 2007, 3:11–17.
23. Hess KR, Serachitopol DM, Brown BW: Hazard function estimators: a
simulation study. Stat Med 1999, 18:3075–3088.
24. Jatoi I, Anderson WF, Jeong JH, Redmond CK: Breast cancer adjuvant
therapy: time to consider its time-dependent effects. J Clin Oncol 2011,
29:2301–2304.
25. Bellera C, MacGrogan G, Debled M, de Lara C, Brouste V, Mathoulin-Pelissier
S: Variables with time-varying effects and the Cox model: Some
statistical concepts illustrated with a prognostic factor study in breast
cancer. BMC Med Res Methodol 2010, 10:20.
26. Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, Cronin
MT, Watson D, Shak S, Bohn OL, Fumagalli D, Taniyama Y, Lee A, Reilly ML,
Vogel VG, McCaskill-Stevens W, Ford LG, Geyer CE Jr, Wickerham DL,
Bianchini et al. Breast Cancer Research 2013, 15:R86 Page 12 of 13
http://breast-cancer-research.com/content/15/5/R86Wolmark N, Paik S: Estrogen receptor (ESR1) mRNA expression and
benefit from tamoxifen in the treatment and prevention of estrogen
receptor-positive breast cancer. J Clin Oncol 2011, 29:4160–4167.
27. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA,
von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M: Outcome
prediction for estrogen receptor-positive breast cancer based on
postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer
Inst 2008, 100:1380–1388.
28. van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM,
Paridaens R, Markopoulos C, Hozumi Y, Hille ET, Kieback DG, Asmar L,
Smeets J, Nortier JW, Hadji P, Bartlett JM, Jones SE: Adjuvant tamoxifen
and exemestane in early breast cancer (TEAM): a randomised phase 3
trial. Lancet 2011, 377:321–331.
29. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L,
Forbes JF, Smith I, Lang I, Wardley A, Rabaglio M, Price KN, Gelber RD,
Coates AS, Thurlimann B: Assessment of letrozole and tamoxifen alone
and in sequence for postmenopausal women with steroid hormone
receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at
8.1 years median follow-up. Lancet Oncol 2011, 12:1101–1108.
30. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF,
Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley
A, Price KN, Goldhirsch A: A comparison of letrozole and tamoxifen in
postmenopausal women with early breast cancer. N Engl J Med 2005,
353:2747–2757.
31. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M,
Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R,
Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R: Meta-analysis of
breast cancer outcomes in adjuvant trials of aromatase inhibitors versus
tamoxifen. J Clin Oncol 2010, 28:509–518.
32. Tang G, Cuzick J, Costantino JP, Dowsett M, Forbes JF, Crager M, Mamounas
EP, Shak S, Wolmark N: Risk of recurrence and chemotherapy benefit for
patients with node-negative, estrogen receptor-positive breast cancer:
recurrence score alone and integrated with pathologic and clinical
factors. J Clin Oncol 2011, 29:4365–4372.
33. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V,
Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni
L, Symmans WF, Pusztai L: Molecular anatomy of breast cancer stroma and
its prognostic value in estrogen receptor-positive and -negative cancers.
JC l i nO n c o l2010, 28:4316–4323.
34. Sgroi D, Sestak I, Cuzick J, Zhang Y, Schnabel C, Erlander M, Goss P, Dowsett M:
Comparative performance of breast cancer index (bci) vs. oncotype dx and
ihc4 in the prediction of late recurrence in hormonal receptor-positive
lymph node-negative breast cancer patients: a TransATAC study.
Cancer Res 2012, 72:S1–9.
35. Dubsky P, Brase JC, Fisch K, Jakesz R, Singer CF, Greil R, Dietze O, Weber KE,
Petry C, Kronenwett R, Rudas M, Knauer M, Gnant M: The EndoPredict
score identifies late distant metastases in ER+/HER2- breast cancer
patients. Cancer Res 2012, 72:S4–3.
doi:10.1186/bcr3481
Cite this article as: Bianchini et al.: Proliferation and estrogen signaling
can distinguish patients at risk for early versus late relapse among
estrogen receptor positive breast cancers. Breast Cancer Research
2013 15:R86.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bianchini et al. Breast Cancer Research 2013, 15:R86 Page 13 of 13
http://breast-cancer-research.com/content/15/5/R86